

# Review of: "Metabolic Reprogramming and Cancer: 2022"

Yanhong Duo<sup>1</sup>

<sup>1</sup> Karolinska Institute Stockholm

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

The authors have submitted their review work to Qeios (Manuscript ID: CK9VJB) titled "Metabolic Reprogramming and Cancer: 2022". The authors have summarized the recent progresses in metabolic reprogramming and cancer, which provided a deeper summary of cancerous metabolism. However, I don't think that manuscript is qualified to be published in Qeios, my concern is listed followed.

1. The quality of manuscript writing is to be improved further with the help or instruction of scientific editors, including the grammar, the style of reference, the format of manuscript and so on.
2. The scope of the manuscript is not fit to the title of manuscript, in the manuscript, the author emphasize the diet in metabolic reprogramming in tumor, therefore, the manuscript should be revised.
3. There are evident shorting of metabolic reprogramming in cancer cells, such as the progresses, metastasis, immune response and so on.
4. Finally, I don't think that this manuscript is of enough novelty.